03.10.2016 • NewsElaine BurridgeNovo NordiskInsulin

Novo Nordisk Axes Jobs to Cut Costs

(c) Novo Nordisk
(c) Novo Nordisk

The world’s biggest insulin producer, Novo Nordisk, has announced plans to cut 1,000 jobs in response to a challenging environment and increased competition, particularly in the US which accounts for about half of its revenue. The Danish drugmaker, which has a global workforce of 42,300, said the layoffs will affect its R&D units and headquarter functions, as well as its global commercial organization. Around 500 of the job losses are expected to be in Denmark.

President and CEO Lars Rebien Sørensen said the move was needed to provide a sustainable balance between income and costs, adding that the company needs to prioritize investments in key product launches that will bring innovation to patients and drive future growth. At its half-year results in August, Novo Nordisk trimmed its full-year profit forecast to the lower end of its previously announced range. It said the job cuts and associated costs did not change its financial outlook for 2016.

Growth has slowed in the key US market where pharmacy benefit managers have been forcing drug companies to offer big discounts for employers and health insurance plans. Nevertheless, Novo Nordisk has high hopes for Tresiba, a new insulin product it launched in the US in January of this year. But the long-acting treatment faces new competitors such as Eli Lilly’s cheaper generic version of Sanofi’s Lantus due to be launched in December, which could limit any price premium that Novo Nordisk might attain for Tresiba.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.